Clinical Trial Update: Study of HS135 in Obese Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction [Phase 1]

View source ↗

Summary

A Phase 1 study of HS135 in obese patients with heart failure with preserved ejection fraction and pulmonary hypertension was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction
• Pulmonary Hypertension

Drugs mentioned

• HS135

Snippet

Sponsor: 35Pharma Inc | Conditions: Heart Failure With Preserved Ejection Fraction, Pulmonary Hypertension | Phase 1 | Status: TERMINATED